We also tested rare LOF variants in SLC39A5 for association with T2D in a multi-ethnic meta-analysis of four studies (UK Biobank, DiscovEHR, Mount Sinai’s BioMe study, and Malmö Diet and Cancer Study), totaling >62,000 cases and >518,000 controls, and found them to be nominally associated with protection from T2D (OR 0.82, 95% CI 0.68–0.99, p=3.7 × 10–2, Figure 1B). The gene discussed is SLC39A5; the disease is cancer.